



AMLODIPINE 2.5mg Film-coated Tablets

- **Indicated for** the treatment of:
 - Hypertension.
 - Chronic stable angina pectoris, and vasospastic angina.
 - The lowest doses available on the market.

The product strength addresses a therapy gap

The dossier is available, and the product is already registered in EU countries

2.5mg complementary strength of amlodipine, which is the recommended starting dose for patients with hepatic insufficiency

Recommended starting dose in patients with hepatic insufficiency

Reference markets

- Amlodipine 2.5mg is registered in Europe.



Regulatory pathway

- Legal basis: Article 10(1) generic application


Development status



- Product registered in Europe

Partnership options

- The product is available for out-licensing in select European markets
- The product is also available for licensing outside of Europe

DISCLAIMER: Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.

 Zentiva Group a.s.
U Kabelovny529/16, 102 00 Prague 10, Czech Republic

 Zent2U@zentiva.com
 +420 267243231

 www.Zent2U.com

ZENTIVA